Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia.
School of Cancer Medicine, La Trobe University, Bundoora, Victoria 3086, Australia.
Biochem Soc Trans. 2019 Feb 28;47(1):109-117. doi: 10.1042/BST20180375. Epub 2019 Jan 9.
Until recently, established cancer cell lines have been used extensively in breast cancer research, due largely to the difficulties associated with the manipulation and long-term maintenance in culture of primary tumour cells from patients. The recent development of organoid cultures has provided new opportunities to model and analyse patient samples, allowing the propagation of malignant cells under conditions that resemble the three-dimensional growth of breast tumours. They have proved efficacious in preserving the heterogeneity of primary samples and are emerging as a new model to further characterise the molecular features of breast cancer. Organoids formed from patient-derived cells are now in use for the evaluation of drug sensitivity and to validate disease-causing genomic variations. Here, the advantages and limitations of organoid cultures will be discussed and compared with the parallel development of other two- and three-dimensional culture strategies and with patient-derived xenografts. In particular, we will focus on the molecular characterisation of breast cancer organoids and provide some examples of how they have been used in functional studies.
直到最近,由于在培养患者的原发性肿瘤细胞方面存在操作和长期维持的困难,已建立的癌细胞系在乳腺癌研究中得到了广泛应用。类器官培养的最新发展为模拟和分析患者样本提供了新的机会,允许在类似于乳腺癌三维生长的条件下恶性细胞的繁殖。它们在保持原发性样本异质性方面已被证明是有效的,并且正在成为进一步表征乳腺癌分子特征的新模型。现在,源自患者来源细胞的类器官正在用于评估药物敏感性和验证导致疾病的基因组变异。在这里,将讨论类器官培养的优缺点,并将其与其他二维和三维培养策略的平行发展以及患者来源的异种移植物进行比较。特别是,我们将重点讨论乳腺癌类器官的分子特征,并提供一些示例,说明它们如何在功能研究中得到应用。